|
| Status |
Public on Nov 14, 2016 |
| Title |
#25-SU223-B3 Ms2 |
| Sample type |
genomic |
| |
|
| Source name |
Engrafted diff iPS from AML_SU223
|
| Organism |
Homo sapiens |
| Characteristics |
sample group: Engrafted diff iPS from AML
subject: SU223
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Genomic DNA was isolated from the indicated populations using standard protocols (Qiagen Inc)
|
| Label |
Cy3 and Cy5
|
| Label protocol |
Standard Ilumina protocol
|
| |
|
| Hybridization protocol |
Bisulphite converted DNA was amplified, fragmented and hybridized to Infinium Methylation 450 arrays using standard Illumina protocol
|
| Scan protocol |
Arrays were scanned using recommened Illumina settings
|
| Data processing |
Beta values were calculated with Minfi v 1.12.0 (Aryee et al 2014)
|
| |
|
| Submission date |
Nov 10, 2016 |
| Last update date |
Nov 16, 2016 |
| Contact name |
Andrew Gentles |
| Organization name |
Stanford University
|
| Street address |
1201 Welch Road
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platform ID |
GPL13534 |
| Series (2) |
| GSE89776 |
Pluripotent Reprogramming of Human AML Resets Leukemic Behavior and Models Therapeutic Targeting of Subclones [methylation] |
| GSE89778 |
Pluripotent Reprogramming of Human AML Resets Leukemic Behavior and Models Therapeutic Targeting of Subclones |
|
